MG53-Mediated Membrane Repair in Muscle Physiology and Disease
MG53 介导的肌肉生理学和疾病中的膜修复
基本信息
- 批准号:8545523
- 负责人:
- 金额:$ 32.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-16 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAnimal ModelBindingBiochemicalBiochemical MarkersBiological ProcessCaveolaeCell membraneCell physiologyCellsCholesterolDYSF geneDataDefectDegenerative DisorderDiseaseDockingFamilial generalized lipodystrophyFunctional disorderGene MutationGoalsHumanInjuryKnock-outLifeLinkLipodystrophyMediatingMembraneModelingMolecularMusMuscleMuscle CellsMuscle FibersMuscular DystrophiesMutationNatural regenerationPaperPhysiologicalPhysiologyPolymerasePreventionProcessProteinsPublishingRNA InterferenceRecoveryRegenerative MedicineRegulationResearch DesignRoleSignal TransductionSiteSkeletal MuscleStructureTRIM FamilyTestingTherapeutic AgentsTranscriptTransgenic OrganismsTranslatingbasecaveolin-3cell injurycellular imaginggenetic manipulationhuman diseaseimprovedin vivoinjuredmembrane assemblymuscular dystrophy mouse modelnovelnovel therapeutic interventionoverexpressionreconstructionrelease factorrepairedresearch and developmentresearch studyresponserestorationsensor
项目摘要
DESCRIPTION (provided by applicant): Repair of acute damage to the plasma membrane is an important aspect of normal cellular physiology and disruption of this process can result in pathophysiology in a number of human diseases including muscular dystrophy. We recently discovered that MG53, a muscle-specific TRIM-family protein, is an essential component of the membrane repair machinery. While our published data define the sensor function for MG53 in cell membrane repair, the molecular mechanisms underlying the nucleation process remain to be defined. Since MG53 can discriminate between intact and injured membrane, a membrane-delimited signal would likely be involved in tethering of MG53 to the injured site. In pilot studie, we found that PTRF is an obligatory factor for MG53-mediated nucleation of the membrane repair response, for cells lacking endogenous expression of PTRF show defective membrane resealing. While RNAi- silencing of PTRF leads to defective membrane repair in muscle fibers, overexpression of PTRF can rescue this defect in dysferlin-/- muscle but not in mg53-/- muscle, suggesting that the functional role of PTRF in membrane repair likely requires the presence of MG53. While many studies have explored the function of PTRF in regulating caveolae structure of the plasma membrane, our data present a new biological function for PTRF as an anchoring molecule for MG53 for initiation of the cell membrane repair response. Since mutations in PTRF have been identified in human disorders with lipodystrophy and muscular dystrophy, conditions that often involve compromised membrane integrity or resealing capacity, targeting the functional interaction between MG53 and PTRF, or restoration of the disrupted MG53-PTRF interaction in the diseased states, may represent an attractive avenue for treatment or prevention of degenerative diseases involving compromised membrane repair. The long-term goal of this project is to understand the cellular and molecular mechanism for membrane repair in muscle physiology and diseases. Specifically, we will focus on testing the hypothesis that "PTRF acts as a docking protein for MG53-mediated cell membrane repair, and restoration of membrane integrity in muscular dystrophy can be achieved through enhancement of MG53/PTRF function at the interface of membrane injury". Our proposed studies will focus on defining the molecular mechanism underlying the functional interaction between MG53 and PTRF for initiation of the cell membrane repair response in skeletal muscle (Aim 1); and exploring the physiological role of MG53 and PTRF in muscle physiology and diseases and test if enhancement of PTRF-MG53 function can improve membrane integrity in muscular dystrophy (Aim 2). Through tailored-expression of MG53 and PTRF and the use of biochemical markers, live cell imaging, ex vivo and in vivo animal model studies, the designed experiments will provide key proof-of-principle data for targeting MG53/PTRF-mediated cell membrane repair in treatment of muscular dystrophy.
描述(由申请人提供):质膜急性损伤的修复是正常细胞生理学的一个重要方面,该过程的破坏可能导致包括肌营养不良在内的许多人类疾病的病理生理学。我们最近发现 MG53,一种肌肉特异性 TRIM 家族蛋白,是膜修复机制的重要组成部分。虽然我们发表的数据定义了 MG53 在细胞膜修复中的传感器功能,但成核过程背后的分子机制仍有待定义。由于 MG53 可以区分完整的膜和受损的膜,膜分隔信号可能参与 MG53 与受损部位的束缚。在初步研究中,我们发现 PTRF 是 MG53 介导的膜修复反应成核的必要因素,因为缺乏 PTRF 内源表达的细胞表现出有缺陷的膜重新密封。虽然 PTRF 的 RNAi 沉默会导致肌纤维中的膜修复缺陷,但 PTRF 的过度表达可以挽救 Dysferlin-/- 肌肉中的这种缺陷,但不能挽救 mg53-/- 肌肉中的这种缺陷,这表明 PTRF 在膜修复中的功能作用可能需要MG53的存在。虽然许多研究探索了 PTRF 在调节质膜小窝结构中的功能,但我们的数据提出了 PTRF 作为 MG53 锚定分子启动细胞膜修复反应的新生物学功能。由于在患有脂肪营养不良和肌营养不良的人类疾病中已经鉴定出 PTRF 突变,这些疾病通常涉及膜完整性或重新密封能力受损,目标是 MG53 和 PTRF 之间的功能相互作用,或在疾病状态下恢复被破坏的 MG53-PTRF 相互作用,可能是治疗或预防涉及膜修复受损的退行性疾病的一种有吸引力的途径。该项目的长期目标是了解肌肉生理学和疾病中膜修复的细胞和分子机制。具体来说,我们将重点检验以下假设:“PTRF充当MG53介导的细胞膜修复的对接蛋白,并且可以通过增强膜损伤界面处的MG53/PTRF功能来恢复肌营养不良症中的膜完整性” 。我们提出的研究将侧重于定义 MG53 和 PTRF 之间功能相互作用的分子机制,以启动骨骼肌细胞膜修复反应(目标 1);探索 MG53 和 PTRF 在肌肉生理学和疾病中的生理作用,并测试增强 PTRF-MG53 功能是否可以改善肌营养不良症中的膜完整性(目标 2)。通过MG53和PTRF的定制表达以及生化标记物、活细胞成像、离体和体内动物模型研究的使用,设计的实验将为靶向MG53/PTRF介导的细胞膜修复提供关键的原理验证数据用于治疗肌营养不良症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jianjie Ma其他文献
Jianjie Ma的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jianjie Ma', 18)}}的其他基金
Multifaceted role of MG53 in alleviating neuromuscular function decline in ALS
MG53 在缓解 ALS 神经肌肉功能衰退中的多方面作用
- 批准号:
10681888 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Mitigating neuroinflammation and enhancing neuronal integrity in Alzheimer's disease
减轻阿尔茨海默病的神经炎症并增强神经元完整性
- 批准号:
10707976 - 财政年份:2022
- 资助金额:
$ 32.83万 - 项目类别:
Ca signaling cross-talk from SR to mitochondria in heart muscle
Ca 信号从 SR 到心肌线粒体的串扰
- 批准号:
9764466 - 财政年份:2018
- 资助金额:
$ 32.83万 - 项目类别:
Myokine function of MG53 in muscle injury-repair and regeneration
MG53在肌肉损伤修复和再生中的肌因子功能
- 批准号:
9924247 - 财政年份:2017
- 资助金额:
$ 32.83万 - 项目类别:
MG53-mediated membrane repair in muscle physiology and disease
MG53 介导的肌肉生理学和疾病中的膜修复
- 批准号:
9103694 - 财政年份:2016
- 资助金额:
$ 32.83万 - 项目类别:
MG53-mediated membrane repair in muscle physiology and disease
MG53 介导的肌肉生理学和疾病中的膜修复
- 批准号:
9770556 - 财政年份:2016
- 资助金额:
$ 32.83万 - 项目类别:
Targeting cell membrane repair for treatment of acute kidney injury
靶向细胞膜修复治疗急性肾损伤
- 批准号:
9102545 - 财政年份:2016
- 资助金额:
$ 32.83万 - 项目类别:
MG53-Mediated Membrane Repair in Muscle Physiology and Disease
MG53 介导的肌肉生理学和疾病中的膜修复
- 批准号:
8574275 - 财政年份:2011
- 资助金额:
$ 32.83万 - 项目类别:
相似国自然基金
肾—骨应答调控骨骼VDR/RXR对糖尿病肾病动物模型FGF23分泌的影响及中药的干预作用
- 批准号:82074395
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
基于细胞自噬调控的苦参碱对多囊肾小鼠动物模型肾囊肿形成的影响和机制研究
- 批准号:
- 批准年份:2019
- 资助金额:33 万元
- 项目类别:地区科学基金项目
靶向诱导merlin/p53协同性亚细胞穿梭对听神经瘤在体生长的影响
- 批准号:81800898
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
伪狂犬病病毒激活三叉神经节细胞对其NF-кB和PI3K/Akt信号转导通路影响的分子机制研究
- 批准号:31860716
- 批准年份:2018
- 资助金额:39.0 万元
- 项目类别:地区科学基金项目
基于中枢胰岛素抵抗探讨自噬失调对肾虚阿尔茨海默的影响及机制研究
- 批准号:81803854
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Role of Dopamine in Cognitive Resilience to Alzheimer's Disease Pathology in Healthy Older Adults
多巴胺在健康老年人阿尔茨海默氏病病理认知弹性中的作用
- 批准号:
10678125 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Prevention of intracellular infection in diabetic wounds by commensal Staphylococcus epidermidis
共生表皮葡萄球菌预防糖尿病伤口细胞内感染
- 批准号:
10679628 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
Design and testing of a novel circumesophageal cuff for chronic bilateral subdiaphragmatic vagal nerve stimulation (sVNS)
用于慢性双侧膈下迷走神经刺激(sVNS)的新型环食管套囊的设计和测试
- 批准号:
10702126 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别:
The Injectrode- An injectable, easily removable electrode as a trial lead for baroreceptor activation therapy to treat hypertension and heart failure
Injectrode——一种可注射、易于拆卸的电极,作为压力感受器激活疗法的试验引线,以治疗高血压和心力衰竭
- 批准号:
10697600 - 财政年份:2023
- 资助金额:
$ 32.83万 - 项目类别: